Slow-moving regulators have kept the rules of engagement on social media platforms fuzzy for pharma players. Yet rather than sit on the sidelines waiting for the […]
In the final part of this three article series exploring how pharma can manage online adverse event reporting, Paul Tunnah concludes his discussion with Siva Nadarajah, […]